CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab

P. Queirolo, B. Dozin, A. Morabito, B. Banelli, R. Carosio, V. Fontana, P.F. Ferrucci, C. Martinoli, E. Cocorocchio, P.A. Ascierto, G. Madonna, E. Simeone, F. De Galitiis, G.C. Antonini Cappellini, P. Marchetti, M. Guida, S. Tommasi, L. Ghilardi, B. Merelli, P. FavaS. Osella-Abate, M. Guidoboni, M. Romani, D. Ferone, F. Spagnolo, M.P. Pistillo, Italian Melanoma Intergroup (IMI)

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalEuropean journal of cancer
Volume97
DOIs
Publication statusPublished - 2018

Keywords

  • cytotoxic T lymphocyte antigen 4
  • ipilimumab
  • cancer immunotherapy
  • cancer survival
  • endocrine disease
  • genetic model
  • genetic variability
  • genotype
  • human
  • hypophysitis
  • Letter
  • metastatic melanoma
  • priority journal
  • single nucleotide polymorphism
  • thyroiditis

Cite this